A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 21, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q1 FY2027, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AMIX SEC filings page.
Autonomix Medical, Inc. (AMIX) reported $0 in revenue for fiscal year 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Autonomix remains a development-stage business: rising research spending and losses are financed largely through new capital rather than operations.
Earnings quality is relatively transparent: FY2026 net loss was$16.7M while operating cash flow was-$12.3M , so reported losses closely tracked cash consumption. But financing provided$10.2M against that outflow, indicating the balance sheet is being replenished externally rather than by business activity.
Development spending accelerated as research and development reached
Liquidity is substantial relative to liabilities but not self-funded: total liabilities were
Financial Health Signals
Autonomix Medical, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Autonomix Medical, Inc. scores -17.06, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $67.1M against total assets of $7.6M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Autonomix Medical, Inc. passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), the one computable operating efficiency signal (asset turnover improving) does not pass.
Autonomix Medical, Inc. reported a net loss of $16.7M while operations used $12.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Autonomix Medical, Inc. generated $0 in revenue in Q1 2027. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Autonomix Medical, Inc.'s EBITDA was -$2.8M in Q1 2027, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Autonomix Medical, Inc. reported a net loss of $2.7M in Q1 2027. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Not reported for Q1 2027.
Cash & Balance Sheet
Autonomix Medical, Inc. held $3.5M in cash as of Q1 2027; no long-term debt figure is on record for that period.
Not reported for Q1 2027.
Not reported for Q1 2027.
Margins & Returns
Autonomix Medical, Inc.'s quarterly ROE was -86.3% in Q1 2027: one quarter's net income over shareholder equity, not annualized. This is down 38.8 percentage points from the same quarter a year earlier.
Not reported for Q1 2027.
Not reported for Q1 2027.
Not reported for Q1 2027.
Capital Allocation
Autonomix Medical, Inc. invested $1.5M in research and development in Q1 2027. This represents a decrease of 4.9% from the same quarter a year earlier.
Not reported for Q1 2027.
Not reported for Q1 2027.
AMIX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0n/m | N/A | $0n/m | $0n/m | $0n/m | N/A | $0n/m | $0n/m |
| R&D Expenses | $1.5M-4.9% | N/A | $1.7M+65.1% | $2.4M+101.6% | $1.6M+67.0% | N/A | $1.0M+52.0% | $1.2M+149.3% |
| SG&A Expenses | $1.3M-31.3% | N/A | $1.6M-4.9% | $5.2M+210.9% | $1.8M+1.6% | N/A | $1.7M-23.9% | $1.7M+109.6% |
| Operating Income | -$2.8Mn/m | N/A | -$3.3Mn/m | -$7.5Mn/m | -$3.4Mn/m | N/A | -$2.7Mn/m | -$2.8Mn/m |
| EBITDA | -$2.8Mn/m | N/A | -$3.3Mn/m | -$7.5Mn/m | -$3.4Mn/m | N/A | -$2.7Mn/m | -$2.8Mn/m |
| Interest Expense | N/A | N/A | $0-100.0% | $0-100.0% | $0-100.0% | N/A | $100K+203.0% | $100Kn/m |
| Income Tax | $0n/m | N/A | $0n/m | $0n/m | $0n/m | N/A | $0n/m | $0n/m |
| Net Income | -$2.7Mn/m | N/A | -$3.3Mn/m | -$7.5Mn/m | -$3.3Mn/m | -$11.4Mn/m | -$2.7Mn/m | -$2.8Mn/m |
| EPS (Basic) | -$5.02 | $0.09 | -$0.36 | -$1.38 | -$22.69 | -$0.74 | -$1.46 | -$2.27n/m |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, EPS (Diluted), Diluted Shares (Avg).
AMIX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $4.0M-55.8% | $7.6M-22.5% | $10.2M-14.6% | $7.9M+47.7% | $9.0M+26.8% | $9.8M+4.2% | $12.0M+560.7% | $5.4M |
| Current Assets | $4.0M-55.8% | $7.6M-21.1% | $10.2M-14.6% | $7.9M+47.4% | $9.0M+26.9% | $9.6M+2.3% | $11.9M+608.1% | $5.4M |
| Cash & Equivalents | $3.5M-59.7% | $7.0M-23.3% | $9.9M-16.0% | $7.5M+45.0% | $8.6M+27.2% | $9.1M+6.1% | $11.8M+870.7% | $5.2M |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0 |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0 |
| Total Liabilities | $818K-58.4% | $1.7M-0.1% | $1.6M-26.5% | $1.5M-36.5% | $2.0M+8.8% | $1.7M-4.0% | $2.2M-69.7% | $2.3M |
| Current Liabilities | $818K-58.4% | $1.7M-0.1% | $1.6M-26.5% | $1.5M+18.3% | $2.0M+157.5% | $1.7M+119.7% | $2.2M+130.7% | $1.3M |
| Non-Current Liabilities | $0n/m | $0n/m | $0n/m | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% | $1.1M |
| Total Equity | $3.2M-55.0% | $5.9M-27.2% | $8.6M-11.8% | $6.4M+112.9% | $7.0M+33.0% | $8.1M+6.2% | $9.7Mn/m | $3.0Mn/m |
| Retained Earnings | -$69.8Mn/m | -$67.1Mn/m | -$64.4Mn/m | -$61.2Mn/m | -$53.7Mn/m | -$50.4Mn/m | -$47.2Mn/m | -$44.5M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
AMIX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.5Mn/m | -$2.9Mn/m | -$3.0Mn/m | -$3.8Mn/m | -$2.6Mn/m | -$8.3Mn/m | -$2.3Mn/m | -$1.6Mn/m |
| Depreciation & Amortization | $3K0.0% | $3K-98.4% | $4K-91.5% | $2K-95.6% | $3K-93.0% | $183K+125.9% | $47K+34.3% | $45Kn/m |
| Stock-Based Compensation | $2K-99.5% | N/A | N/A | N/A | $388K+7.8% | $1.6M+163.4% | N/A | N/A |
| Capital Expenditures | N/A | $3K-78.6% | $7K+40.0% | $0n/m | $0-100.0% | $14K-26.3% | $5K-68.8% | $0n/m |
| Free Cash Flow | N/A | -$2.9Mn/m | -$3.0Mn/m | -$3.8Mn/m | -$2.6Mn/m | -$8.3Mn/m | -$2.3Mn/m | -$1.6Mn/m |
| Investing Cash Flow | N/A | -$3Kn/m | -$7Kn/m | $0n/m | $0n/m | -$14Kn/m | -$5Kn/m | $0n/m |
| Financing Cash Flow | $0-100.0% | -$35K-100.4% | $5.4M-39.5% | $2.7Mn/m | $2.1Mn/m | $8.8M-38.9% | $9.0M+445.5% | $0-100.0% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
AMIX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -86.3%-38.8pp | N/A | -38.1%-10.2pp | -115.6%-22.9pp | -47.4%+3.6pp | -140.9%+61.3pp | -27.9% | -92.7% |
| Return on Assets | -68.5%-31.4pp | N/A | -31.9%-9.3pp | -93.9%-41.7pp | -37.1%+1.0pp | -116.4%+47.6pp | -22.7%+149.4pp | -52.3% |
| Current Ratio | 4.85+0.3x | 4.45-1.2x | 6.18+0.9x | 5.31+1.0x | 4.57-4.7x | 5.63-6.5x | 5.31+3.6x | 4.26 |
| Liabilities-to-Equity | 0.260.0x | 0.29+0.1x | 0.190.0x | 0.23-0.5x | 0.28-0.1x | 0.210.0x | 0.23 | 0.77 |
| Asset Turnover | 0.000.0x | N/A | 0.000.0x | 0.000.0x | 0.000.0x | N/A | 0.000.0x | 0.00 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Autonomix Medical, Inc. AMIX | FY2026 | $0 | -$16.7M | N/A | $5.0M | — |
| Corvex, Inc. MOVE | FY2025 | $433K | -$18.3M | N/A | $266.6M | — |
| HeartSciences Inc. HSCS | FY2026 | $4K | -$9.1M | N/A | $17.2M | — |
| BIOMERICA INC BMRA | FY2026 | $4.5M | -$3.8M | -84.8% | $7.9M | 45/100 |
| Solana Company HSDT | FY2025 | $6.0M | -$40.9M | N/A | $153.6M | 38/100 |
Where Autonomix Medical, Inc. Ranks
Frequently Asked Questions
What is Autonomix Medical, Inc.'s annual revenue?
Autonomix Medical, Inc. (AMIX) reported $0 in total revenue for fiscal year 2026. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Autonomix Medical, Inc. profitable?
No, Autonomix Medical, Inc. (AMIX) reported a net loss of $16.7M in fiscal year 2026.
What is Autonomix Medical, Inc.'s EBITDA?
Autonomix Medical, Inc. (AMIX) had EBITDA of -$17.0M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
What is Autonomix Medical, Inc.'s return on equity (ROE)?
Autonomix Medical, Inc. (AMIX) has a return on equity of -283.6% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is Autonomix Medical, Inc.'s free cash flow?
Autonomix Medical, Inc. (AMIX) recorded an outflow of $12.3M in free cash flow during fiscal year 2026. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Autonomix Medical, Inc.'s operating cash flow?
Autonomix Medical, Inc. (AMIX) recorded an outflow of $12.3M in operating cash flow during fiscal year 2026, representing cash used by core business activities.
What are Autonomix Medical, Inc.'s total assets?
Autonomix Medical, Inc. (AMIX) had $7.6M in total assets as of fiscal year 2026, including both current and long-term assets.
What are Autonomix Medical, Inc.'s capital expenditures?
Autonomix Medical, Inc. (AMIX) invested $10K in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
How much does Autonomix Medical, Inc. spend on research and development?
Autonomix Medical, Inc. (AMIX) invested $7.1M in research and development during fiscal year 2026.
What is Autonomix Medical, Inc.'s current ratio?
Autonomix Medical, Inc. (AMIX) had a current ratio of 4.45 as of fiscal year 2026, which is generally considered healthy.
What is Autonomix Medical, Inc.'s liabilities-to-equity ratio?
Autonomix Medical, Inc. (AMIX) had a liabilities-to-equity ratio of 0.29 as of fiscal year 2026, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2026, because the filing data we hold for that year carries no long-term debt figure.
What is Autonomix Medical, Inc.'s return on assets (ROA)?
Autonomix Medical, Inc. (AMIX) had a return on assets of -219.9% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is Autonomix Medical, Inc.'s P/E ratio?
Autonomix Medical, Inc. (AMIX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2026). The market capitalization is $5.0M as of Oct 21, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Autonomix Medical, Inc.'s price-to-sales ratio?
Autonomix Medical, Inc. (AMIX) has no price-to-sales ratio at the moment: revenue is not positive (FY2026). The market capitalization is $5.0M as of Oct 21, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Autonomix Medical, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2026, Autonomix Medical, Inc. (AMIX) held $7.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $12.3M over that year. Dividing the one by the other, the reported balance equals about 7 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Autonomix Medical, Inc.'s Altman Z-Score?
Autonomix Medical, Inc. (AMIX) has an Altman Z-Score of -17.06, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Autonomix Medical, Inc.'s Piotroski F-Score?
Autonomix Medical, Inc. (AMIX) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Autonomix Medical, Inc.'s earnings high quality?
Autonomix Medical, Inc. (AMIX) reported a net loss of $16.7M while operations used $12.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.